Non-motor symptoms (NMS) are common among patients with Parkinson’s disease and reduce patients’ quality of life (QOL). However, there remain considerable unmet needs for NMS management. Three monoamine oxidase B inhibitors (MAO-BIs), selegiline, rasagiline, and safinamide, have become commercially available in many countries. Although an increasing number of studies have reported potential beneficial effects of MAO-BIs on QOL and NMS, there has been no consensus. Thus, the primary objective of this study was to provide an up-to-date systematic review of the QOL and NMS outcomes from the available clinical studies of MAO-BIs. We conducted a literature search using the PubMed, Scopus, and Cochrane Library databases in November 2021. We identified 60 publications relevant to this topic. Overall, rasagiline and safinamide had more published evidence on QOL and NMS changes compared with selegiline. This was likely impacted by selegiline being introduced many years prior to the field embarking on the study of NMS. The impact of MAO-BIs on QOL was inconsistent across studies, and this was unlikely to be clinically meaningful. MAO-BIs may potentially improve depression, sleep disturbances, and pain. In contrast, cognitive and olfactory dysfunctions are likely unresponsive to MAO-BIs. Given the paucity of evidence and controlled, long-term studies, the effects of MAO-BIs on fatigue, autonomic dysfunctions, apathy, and ICD remain unclear. The effects of MAO-BIs on static and fluctuating NMS have never been investigated systematically. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on a non-motor symptom profile.

非运动症状 (NMS) 在帕金森病患者中很常见，会降低患者的生活质量 (QOL)。然而，对于 NMS 管理仍有相当多的需求未得到满足。三种单胺氧化酶 B 抑制剂 (MAO-BI)，司来吉兰、雷沙吉兰和沙非酰胺，已在许多国家上市。尽管越来越多的研究报告了 MAO-BIs 对 QOL 和 NMS 的潜在有益影响，但尚未达成共识。因此，本研究的主要目的是对现有的 MAO-BI 临床研究的 QOL 和 NMS 结果进行最新的系统评价。我们于 2021 年 11 月使用 PubMed、Scopus 和 Cochrane 图书馆数据库进行了文献检索。我们确定了 60 篇与该主题相关的出版物。全面的，与司来吉兰相比，雷沙吉兰和沙非酰胺有更多关于 QOL 和 NMS 变化的已发表证据。这可能是由于在该领域开始研究 NMS 之前多年引入了司来吉兰。MAO-BIs 对 QOL 的影响在各个研究中不一致，这不太可能具有临床意义。MAO-BI 可能会改善抑郁、睡眠障碍和疼痛。相反，认知和嗅觉功能障碍可能对 MAO-BI 没有反应。鉴于缺乏证据和对照的长期研究，MAO-BIs 对疲劳、自主神经功能障碍、冷漠和 ICD 的影响仍不清楚。MAO-BIs 对静态和波动 NMS 的影响从未被系统地研究过。